5 results
The current study is set up to validate the working mechanism of the current design of the FemFlow.
Comparison of steady-state cysteamine-trough WBC cystine levels between Cystagon® and RP103 over 3 months for each treatment period.
Primary objective:Non-invasively determining the 11C-erlotinib brain uptake in DIPG patients by PET imaging.Secondary objective:Determining the EGFR expression in DIPG
- To assess the pharmacokinetic profile of cysteamine base after single dose administration of the new sustained-release cysteamine bitartrate (PO-001) to healthy volunteers, in comparison with Cystagon® and Procysbi®.- To collect safety/…
Primary Objective: This study is set up to validate the patient comfort of the current design of the FemFlow. For the validation of the patient comfort, the FemFlow will be rated on:Comfort during insertion Comfort of an alien object in the bladder…